Skip to main content
Publications
Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C. Recovery from Opioid Use Disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study. J Addict Med. 2020 Sep;14(5):e233-40. doi: 10.1097/ADM.0000000000000647
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study. J Addict Med. 2019 Nov;13(6):442-9. doi: 10.1097/ADM.0000000000000517.
Rashid S, Januwalla A, Moore J, Park J, Rup J, Khan A, Straus SE, Tu J, CANHEART SPOR Research Team 2. The Cardiovascular Health in Ambulatory Care Research Team (CANHEART) Initiative: using implementation science to improve dyslipidemia management in Ontario. Poster presented at the International Symposium on Atherosclerosis (ISA) 2018; June 9, 2018. Toronto, Canada. [abstract] Atherosclerosis. 2018 Jun; 32:54-5. doi: 10.1016/j.atherosclerosissup.2018.04.164
Granero R, Fernandez-Aranda F, Aymami N, Gomez-Pena M, Fagundo AB, Sauchelli S, del Pino-Gutierrez A, Moragas L, Savvidou LG, Islam MA, Tarrega S, Menchon JM, Jimenez-Murcia S. Subtypes of pathological gambling with concurrent illegal behaviors. J Gambl Stud. 2015 Dec;31(4):1161-78. doi: 10.1007/s10899-014-9499-5.
Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005;183(2):283-92.
Morange PE, Saut N, Alessi MC, Frere C, Hawe E, Yudkin JS, Tremoli E, Margaglione M, di Minno G, Hamsten A, Humphries SE, Juhan-Vague I, HIFMECH Study Group. HIFMECH Study Group. Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis. 2005;179(2):317-23.
Elrayess MA, Webb KE, Bellingan GJ, Whittall RA, Kabir J, Hawe E, Syvänne M, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Miller GJ, Humphries SE. R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis. 2004;177(1):105-12.